CYIOS Corp Reports Record $5 Million in Q4 Revenue Through Noir Subsidiary; Noir Full-Year Revenue Exceeds $14.4 Million
CYIOS Corp has announced record-breaking financial results through its subsidiary Noir Medical Supplies. The company reported Q4 2024 revenue of $5 million, with Noir's full-year revenue exceeding $14.4 million, marking a 200% increase from $4.55 million in 2023.
Following the Noir acquisition completed on August 10, 2024, CYIOS achieved significant milestones: $2.93 million revenue in Q3 2024 (Aug 10-Sep 30) and over $8 million in total revenue post-acquisition through December 31.
For 2025, CYIOS plans to scale Noir with expanded product offerings and geographic reach, forecasting $15+ million in revenue. The company is pursuing an uplisting strategy to OTCQB or higher, including completion of a two-year PCAOB audit to enhance financial transparency.
CYIOS Corp ha annunciato risultati finanziari da record attraverso la sua filiale Noir Medical Supplies. L'azienda ha riportato un fatturato del quarto trimestre 2024 di 5 milioni di dollari, con un fatturato complessivo di Noir che supera i 14,4 milioni di dollari, segnando un aumento del 200% rispetto ai 4,55 milioni di dollari del 2023.
Dopo l'acquisizione di Noir completata il 10 agosto 2024, CYIOS ha raggiunto traguardi significativi: 2,93 milioni di dollari di fatturato nel terzo trimestre 2024 (dal 10 agosto al 30 settembre) e oltre 8 milioni di dollari di fatturato totale post-acquisizione fino al 31 dicembre.
Per il 2025, CYIOS pianifica di espandere Noir con una maggiore offerta di prodotti e una maggiore portata geografica, prevedendo oltre 15 milioni di dollari di fatturato. L'azienda sta perseguendo una strategia di uplisting verso OTCQB o superiore, inclusa la conclusione di una revisione PCAOB biennale per migliorare la trasparenza finanziaria.
CYIOS Corp ha anunciado resultados financieros récord a través de su filial Noir Medical Supplies. La compañía reportó ingresos del cuarto trimestre de 2024 de 5 millones de dólares, con ingresos anuales de Noir que superan 14,4 millones de dólares, lo que representa un aumento del 200% respecto a los 4,55 millones de dólares de 2023.
Tras la adquisición de Noir completada el 10 de agosto de 2024, CYIOS alcanzó hitos significativos: 2,93 millones de dólares en ingresos en el tercer trimestre de 2024 (del 10 de agosto al 30 de septiembre) y más de 8 millones de dólares en ingresos totales posteriores a la adquisición hasta el 31 de diciembre.
Para 2025, CYIOS planea escalar Noir con una oferta de productos ampliada y un alcance geográfico mayor, pronosticando más de 15 millones de dólares en ingresos. La compañía está llevando a cabo una estrategia de uplisting hacia OTCQB o superior, incluida la finalización de una auditoría PCAOB de dos años para mejorar la transparencia financiera.
CYIOS Corp는 자회사 Noir Medical Supplies를 통해 기록적인 재무 결과를 발표했습니다. 회사는 2024년 4분기 매출이 500만 달러에 이르렀으며, Noir의 연간 매출은 1440만 달러를 초과하고, 이는 2023년의 455만 달러 대비 200% 증가한 수치입니다.
2024년 8월 10일 Noir의 인수 완료 이후, CYIOS는 의미 있는 이정표를 세웠습니다: 2024년 3분기(8월 10일부터 9월 30일까지) 매출이 293만 달러에 달하며, 인수 후 12월 31일까지 총 매출이 800만 달러를 초과했습니다.
2025년을 위해 CYIOS는 Noir를 확장된 제품 제공과 지리적 범위를 통해 발전시킬 계획이며, 1500만 달러 이상의 매출을 예상하고 있습니다. 회사는 재무 투명성을 높이기 위해 2년간의 PCAOB 감사 완료를 포함한 OTCQB 또는 그 이상의 상장 전략을 추구하고 있습니다.
CYIOS Corp a annoncé des résultats financiers historiques grâce à sa filiale Noir Medical Supplies. La société a rapporté des revenus de 5 millions de dollars pour le quatrième trimestre 2024, Noir ayant dépassé un chiffre d'affaires annuel de 14,4 millions de dollars, marquant une augmentation de 200 % par rapport aux 4,55 millions de dollars en 2023.
Suite à l'acquisition de Noir, achevée le 10 août 2024, CYIOS a atteint des étapes significatives : un chiffre d'affaires de 2,93 millions de dollars au troisième trimestre 2024 (du 10 août au 30 septembre) et plus de 8 millions de dollars de chiffre d'affaires total après l'acquisition jusqu'au 31 décembre.
Pour 2025, CYIOS prévoit d'étoffer Noir avec une gamme de produits élargie et une portée géographique accrue, visant des revenus de plus de 15 millions de dollars. L'entreprise poursuit une stratégie de remontée vers OTCQB ou plus, y compris l'achèvement d'un audit PCAOB de deux ans pour améliorer la transparence financière.
CYIOS Corp hat über seine Tochtergesellschaft Noir Medical Supplies rekordverdächtige finanzielle Ergebnisse bekannt gegeben. Das Unternehmen meldete im vierten Quartal 2024 Einnahmen von 5 Millionen Dollar, während Noir im Gesamtjahr Einnahmen von über 14,4 Millionen Dollar erzielte, was einem Anstieg von 200 % gegenüber den 4,55 Millionen Dollar im Jahr 2023 entspricht.
Nach dem am 10. August 2024 abgeschlossenen Erwerb von Noir erzielte CYIOS bedeutende Meilensteine: 2,93 Millionen Dollar Umsatz im dritten Quartal 2024 (vom 10. August bis 30. September) und über 8 Millionen Dollar Gesamteinnahmen nach der Übernahme bis zum 31. Dezember.
Für 2025 plant CYIOS, Noir mit einem erweiterten Produktangebot und geografischer Reichweite zu skalieren und erwartet Einnahmen von über 15 Millionen Dollar. Das Unternehmen verfolgt eine Strategie zur Auflistung an OTCQB oder höher, einschließlich des Abschlusses einer zweijährigen PCAOB-Prüfung zur Verbesserung der finanziellen Transparenz.
- Record Q4 2024 revenue of $5 million
- Full-year 2024 revenue of $14.4 million, exceeding initial $7-9 million expectations
- 200% year-over-year revenue growth from $4.55 million in 2023
- Post-acquisition revenue of $8 million (Aug 10-Dec 31, 2024)
- Projected revenue of $15+ million for 2025
- None.
2024 marks a transformative year for CYIOS Corp, with Noir achieving over
BOCA RATON, FL / ACCESS Newswire / January 16, 2025 / CYIOS Corp (OTC PINK:CYIO) is pleased to announce that its wholly-owned subsidiary, Noir Medical Supplies, delivered a record-breaking
"2024 was a transformative year for CYIOS," stated Chairman John O'Shea. "The extraordinary success of our Noir acquisition, which closed on August 10th, has not only strengthened our financial position but also set the foundation for a successful 2025."
2024 Year in Review
Noir Acquisition: Completed on August 10, 2024, the acquisition has been instrumental in driving revenue growth.
Revenue Milestones:
CYIOS Q3 2024 (August 10 - September 30):
$2.93 million in revenue.CYIOS Q4 2024: Surpassed
$5 million in revenue, marking the highest quarterly revenue in the company's history.Total revenue from Noir post-acquisition (August 10 - December 31): Over
$8 million .Noir's full-year 2024 revenue: Surpassed
$14.4 million , significantly exceeding initial expectations of$7 -$9 million .
2025 Roadmap and Strategic Focus
CYIOS Corp remains focused on delivering continued revenue growth with a solid foundation firmly in place. Key initiatives for 2025 include:
1. Scaling Noir:
Expanding product offerings and enhancing geographic reach.
Forecasting
$15 + million in revenue for Noir in 2025, excluding potential acquisitions.
2. Uplisting Strategy
Completing a two-year PCAOB audit to enhance financial transparency
Aiming for an exchange uplisting to OTCQB or higher
Closing Remarks
"CYIOS Corp is well-positioned to build on its momentum from 2024," said O'Shea, Chairman of CYIOS Corp. "We are confident investors will take notice of our new direction, successful execution driving revenue growth and delivering sustainable value for shareholders in 2025 and beyond. By focusing on revenue growth and margin expansion as the cornerstone of our strategy, we aim to create significant long-term shareholder value. With Noir now having completed two quarters under CYIOS, we anticipate consistent performance that will garner increased attention from the investment community.
We also believe an uplisting to a higher-tier exchange could substantially enhance shareholder value, providing access to a broader investor base. As we continue to execute successfully and address the disparity between Noir revenues-exceeding
About Noir Medical Supplies
Noir Medical Supplies is a rapidly growing provider of high-quality medical supplies and equipment, offering products from personal protective equipment (PPE) to essential healthcare items for clinics, hospitals, and medical professionals. Founded in 2023, Noir's mission is to solve inventory challenges for healthcare distributors and institutions across the United States and the Caribbean by delivering high-quality products at competitive prices. Noir serves some of the nation's largest healthcare and biotech companies and continues to expand its reach to meet the evolving needs of the healthcare sector.
Additional information regarding clients served as well as distribution partners can be found on the company's website. (https://noirmedicalsupplies.com/)
CYIOS Contact Information
Investors are encouraged to follow CYIOS at: https://twitter.com/cyioscorp
https://www.tiktok.com/@cyioscorp
Public and Investor Relations: admin@cyioscorporation.com
About CYIOS Corporation
CYIOS Corp (OTC PINK: CYIO) is a publicly traded company focused on strategic investments and acquisitions in high-growth sectors, including healthcare, medical technology, and emerging industries. CYIOS Corp is committed to building a portfolio that delivers long-term value to shareholders through innovation and excellence. For more information, please visit: CYIOScorporation.com.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements." Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management's current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified using words such as "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "would," "could," "will" & other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company's actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. Any forward-looking information provided in this release should be considered w/ these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.
SOURCE: CYIOS Corp.
View the original press release on ACCESS Newswire
FAQ
What was CYIOS Corp's (CYIO) Q4 2024 revenue?
How much revenue did Noir generate for CYIOS (CYIO) in full-year 2024?
What was the year-over-year revenue growth for CYIOS's (CYIO) Noir subsidiary in 2024?
What is CYIOS Corp's (CYIO) revenue forecast for Noir in 2025?
When did CYIOS Corp (CYIO) complete the Noir acquisition?
What are CYIOS Corp's (CYIO) uplisting plans for 2025?
